Codexis to Report Third Quarter 2025 Financial Results on November 6
Rhea-AI Summary
Codexis (NASDAQ: CDXS) will report third quarter 2025 financial results on Thursday, November 6, 2025, after market close. Management will host a conference call and live webcast at 4:30 PM Eastern Time to discuss results and provide a business update.
Investors can access the live webcast on the Codexis Investor Relations website; the webcast will be archived for 90 days. A telephone replay will be available for 48 hours with access ID 13726635.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CDXS gained 1.17%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
REDWOOD CITY, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the third quarter of 2025 on Thursday, November 6, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update.
Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the call will be available for 48 hours by dialing 877-660-6853 (domestic) or 201-612-7415 (international), access ID #13726635.
About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.
For More Information
Georgia Erbez
Chief Financial Officer
Codexis, Inc.
(650) 421-8100
ir@codexis.com
FAQ
When will Codexis (CDXS) report Q3 2025 results?
What time is the Codexis Q3 2025 earnings call and webcast?
How can I access the Codexis (CDXS) live webcast for Q3 2025?
What are the telephone numbers and replay details for the Codexis Q3 2025 call?
Will Codexis management provide a business update on the Q3 2025 call?
Where will the Codexis Q3 2025 webcast be archived and for how long?
